Drug Profile
CPD 100
Alternative Names: CPD-100; CPD-100LiLatest Information Update: 26 Oct 2023
Price :
$50
*
At a glance
- Originator Novacea
- Developer Cascade Prodrug
- Class Antineoplastics; Vinca alkaloids
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 26 Oct 2023 PK, PD and adverse events data from a preclinical studies in indication) released by cascade prodrug prior to October 2023 (Cascade prodrug pipeline, October 2023)
- 07 Dec 2022 Preclinical development is ongoing in USA
- 01 Oct 2022 CPD 100 receives Orphan Drug status for Pancreatic cancer in USA